Purchasing, possessing, or administering unlicensed substances carries both legal and significant health risks
Safety signals of special interest, including pancreatitis, gallbladder events, neoplasms, and suicidal ideation, were adjudicated by blinded expert committees
Neither compound is approved by Health Canada for therapeutic use, and both are prohibited by the World Anti-Doping Agency
Athletes should complete the TUE Pre-Check Form to confirm whether they need a TUE before applying
Reta/Cagri Blend 12.5mg/2.5mg This research peptide blend contains 12.5mg of Retatrutide and 2.5mg of Cagrilintide in a lyophilized powder format
It was first identified in 1973 by Loren Pickart, who observed that this fragment naturally present in human plasma at roughly 200 ng/mL in young adults declined with age and appeared to influence tissue repair